Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Buisson

Showing results (51-60 of 166) with videos related to

Pageof 17
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 24, 2016
Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn's diseaseStéphanie Decousus, Anne-Laure Boucher, Juliette Joubert, et al.
Gut Microbes|November 25, 2025
Persistence mechanisms of Crohn's disease-associated adherent invasive <i>Escherichia coli</i> within macrophagesEmma Bruder, Hosni Nedjar, Nicole Quenech'Du, et al.
Journal of Clinical Gastroenterology|August 18, 2025
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease: An individual participant data meta-analysisFraser Cummings, Philip J Smith, Mathurin Fumery, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 19, 2023
Positive margins and plexitis increase the risk of recurrence after ileocecal resection: A systematic review and meta-analysisClara Yzet, Clémentine Riault, Franck Brazier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2022
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyAnthony Buisson, Maria Nachury, Maud Reymond, et al.
Clinics and Research in Hepatology and Gastroenterology|February 5, 2025
Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of inflammatory bowel diseaseSerge Dubian, Clara Yzet, Franck Brazier, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapyLuc Manlay, Gilles Boschetti, Bruno Pereira, et al.
Gut Microbes|October 14, 2024
ChiA: a major player in the virulence of Crohn's disease-associated adherent and invasive <i>Escherichia coli</i> (AIEC)Margot Fargeas, Frederic Faure, Clara Douadi, et al.
Digestive Diseases and Sciences|April 13, 2017
Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic FailureCécile Campos, Antoine Perrey, Céline Lambert, et al.
Inflammatory Bowel Diseases|October 27, 2020
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease LocationAnthony Buisson, Wing Yan Mak, Michael J Andersen, et al.
Pageof 17

Showing results (51-60 of 166) with videos related to

Sort By:
Pageof 17
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 24, 2016
Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn's diseaseStéphanie Decousus, Anne-Laure Boucher, Juliette Joubert, et al.
Gut Microbes|November 25, 2025
Persistence mechanisms of Crohn's disease-associated adherent invasive <i>Escherichia coli</i> within macrophagesEmma Bruder, Hosni Nedjar, Nicole Quenech'Du, et al.
Journal of Clinical Gastroenterology|August 18, 2025
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease: An individual participant data meta-analysisFraser Cummings, Philip J Smith, Mathurin Fumery, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 19, 2023
Positive margins and plexitis increase the risk of recurrence after ileocecal resection: A systematic review and meta-analysisClara Yzet, Clémentine Riault, Franck Brazier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2022
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyAnthony Buisson, Maria Nachury, Maud Reymond, et al.
Clinics and Research in Hepatology and Gastroenterology|February 5, 2025
Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of inflammatory bowel diseaseSerge Dubian, Clara Yzet, Franck Brazier, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapyLuc Manlay, Gilles Boschetti, Bruno Pereira, et al.
Gut Microbes|October 14, 2024
ChiA: a major player in the virulence of Crohn's disease-associated adherent and invasive <i>Escherichia coli</i> (AIEC)Margot Fargeas, Frederic Faure, Clara Douadi, et al.
Digestive Diseases and Sciences|April 13, 2017
Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic FailureCécile Campos, Antoine Perrey, Céline Lambert, et al.
Inflammatory Bowel Diseases|October 27, 2020
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease LocationAnthony Buisson, Wing Yan Mak, Michael J Andersen, et al.
Pageof 17